Communications
BluMaiden Biosciences – Revolutionizing Drug Discovery
In this article, I spoke to Dr Damien Keogh, founder and CEO of BlueMaiden Biosciences about his experience at raising and expanding a start-up in a post-COVID environment.
Communications
2024 Is A Historic Year for Fatty Liver Disease. What’s Next?
On 14 March 2024, the U.S. Food and Drug Administration (FDA) approved the first treatment for noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise [1]. NASH is the more serious stage of non-alcoholic fatty liver disease (NAFLD), a silent killer affecting up to 40% of the population in Singapore [2].
Career Series
BCS Career Interviews – Prof. Ooi Eng Eong, SAB member of Arcturus Therapeutics
The third article of the career series interviews with Prof. Ooi Eng Eong, Professor in the Programme in Emerging Infectious Diseases at Duke-NUS. Prof Ooi also serves as a Scientific Advisory Board (SAB) member for Arcturus Therapeutics. Read on as Prof Ooi discusses his journey to become an SAB board member and the role the SAB plays in biotech start-ups.
Academics to Industry
Synthetic Biology and Sustainable Cosmetics
In this article, we explore the innovative technology of Allozymes, a Singaporean-grown start-up that is paving the way in enzyme engineering to create a more sustainable future. Read on to understand how synthetic biology and microfluidics can contribute to a greener cosmetics industry, and other future applications!
Communications
From Bugs to Drugs: Harnessing the Power of Microbes as Living Medicines
The 1st BCS Biotech Writing Competition was held in 2023 where applicants submitted their entries on current biotechnology trends and opinions in Asia. In the wake of the COVID-19 pandemic and the perpetual outbreaks of Influenza, most of us see microbes as dangerous organisms. Our 3rd prize winner, Vanessa Lunardi, writes an informative piece that proves otherwise – maybe microbes can be used to benefit humankind after all.
Communications
Cell-ing Southeast Asia
The 1st BCS Biotech Writing Competition was held in 2023 where applicants submitted their entries on current biotechnology trends and opinions in Asia. Our 1st runner up, Yap Wee Swan, provides a comprehensive, yet personal, perspective of cellular agriculture in Southeast Asia.
Communications
Does precision health screening wear Prada?
The 1st BCS Biotech Writing Competition was held in 2023 where applicants submitted their entries on current biotechnology trends and opinions in Asia. The winning entry by Jingmei Li, PhD shares about precision health screening through personal anecdotes, and its potential applications in early detection of diseases.
Career Series
BCS Career Interviews – Dr. Wen Qi Ho of ClavystBio
The second article of the career series interviews Dr. Wen Qi Ho, previous Vice-President of Lightstone Ventures and current Director of Investments and New Ventures at ClavystBio. Read on to learn more about the transition from academia to VC.
Career Series
BCS Career Interviews – Dr. Peyman Salehian of Allozymes
Wonder what it’s like to be a founder of a deep-tech company in Singapore? Biotech Connection Singapore is kickstarting our Career Series Interviews again! In this interview, we speak with Dr. Peyman Salehian, co-founder and CEO of Singapore-based startup Allozymes. What does it take to make a deep-tech company like Allozymes work? What are the challenges one must be prepared to face? And what takeaways can we glean from Dr. Peyman’s experiences? Read on to find out more.
Communications
‘Senolytics’ – The cure for ageing?
Senescence and aging are two terms that many are not familiar with, and they come with their fair share of associated maladies. But with the recent discovery of senolytics, is it possible to halt aging in its tracks? In this joint collaboration with A*STAR, we discuss the current progress and potential of senolytics.